Compare AFLAC Incorporated (AFL) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AFLAC Incorporated vs TransMedics Group Inc — how do they compare? AFLAC Incorporated trades at $121.27 (market cap $61.84B), while TransMedics Group Inc trades at $70.28 (market cap $2.46B). The key difference: AFLAC Incorporated is far larger — about 25.1× TransMedics Group Inc's market cap, and AFLAC Incorporated pays a 2.01% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| AFL | TMDX | |
|---|---|---|
Market Cap | $61.84B | $2.46B |
Sector | Financials | Technology |
52-Week High | $121.49 | $150.42 |
52-Week Low | $98.09 | $61.99 |
Enterprise Value | $70.50B | $2.86B |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aflac (AFL) trades at $121.49, up 0.5% with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with a 25.32% net income margin and 16.47% ROE, though recent Q1 2026 earnings missed expectations. Analyst consensus is mixed with 28% buy ratings and a $113.57 price target below current levels. Recent developments include strong dividend performance and upcoming Q2 2026 results announcement on August 6, 2026.
The outlook remains cautiously optimistic with solid profitability and dividend stability, but faces headwinds from recent earnings misses and premium valuation pressure. Key opportunities include continued growth in Japan and U.S. markets, while risks involve medical cost inflation and uneven revenue trends. The stock's current premium to analyst targets suggests limited near-term upside potential.
TMDX trades at $71.23, up 3.44% on the day, but technical indicators signal a bearish trend. The company reported strong profitability with a 27.04% net income margin and 45.22% ROE for 2025, though Q1 2026 earnings missed expectations. Recent strategic investments in European organ logistics aim to expand its competitive moat, but margin pressure from expansion costs is a key concern noted by analysts (Zacks Investment Research, 2026-07-07).
The investment outlook is mixed: strong analyst consensus (75% buy ratings) and a $108.71 price target suggest significant upside, but near-term execution risks and bearish technicals warrant caution. Long-term growth drivers in transplant logistics are compelling, yet investors must weigh expansion costs against the potential for market share gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AFLAC Incorporated
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Read more on AFL →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
